




ILCA Annual Conference **2025**


Hong Kong
19-21 November

国际肝癌协会 ILCA 2025年度会议



18 November
ILCA
Masterclass

PROVISIONAL PROGRAMME





REGISTRATION

Registration must be completed online at [Registration – ILCALive](#)

ILCA members benefit from special registration fees. If you'd like to become a member, simply sign up today and benefit from the many advantages and join the ILCA community.

Attendee Category	Super Early Bird (until 7 th of April)	Early Bird (until 29 th of May)	Regular Fee (until 17 th of November)	On-Site Fee (18 th to 21 st November)
ILCA Member	320	420	535	595
Non-Member	520	690	745	800
Student ILCA Member	165	180	215	240
Student Non-Member	206	227	265	290
Nurse / Pharmacist member	165	180	215	240
Nurse / Pharmacist non -member	206	227	265	290
Virtual only fee	258	280	370	370

VIRTUAL REGISTRATION:

UNABLE TO JOIN US IN HONG KONG?

Participate virtually in **ILCA25** and access sessions from the comfort of your own space. Please note that the sessions are not live streamed, but with the Virtual Pass you will have access to the recordings which will be available 48 hours after the end of the Conference.

VENUE & ACOMMODATION

The venue for ILCA AC2025 is the [Hong Kong Ocean Park Marriott Hotel](#).

Please visit <https://ilcalive.org> for future information and for hotel reservations.

Through this website you can reserve, modify or cancel your reservations at any time and receive updated information about the event.

We look forward to seeing you!





ILCA PRE CONFERENCE MASTERCLASS

In line with our commitment to supporting the future generations of hepatology professionals, we're excited to invite junior doctors and early-career academics to our exclusive pre-conference masterclass.

Taking place just before our Annual Conference, this masterclass is perfect for young researchers looking to explore the latest breakthroughs in HCC, from radiological diagnosis to liver transplant, surgery, and systemic therapies.

Time	Title	Speakers
Session I: Latest update on the landscape of HCC - Chairs: Pierce Chow, Stephen Chan		
9:15-9:30am	Opening	Stephen Chan (HK)
9:30-9:50am	Radiological diagnosis of HCC: What's new	Hanyu Jiang (China)
9:50-10:10am	Liver transplant and Surgery	Pierce Chow (Singapore)
10:10-10:30am	Updates on systemic therapy for HCC	Maria Reig (Spain)
10:30-11:00am	Q&A	
11:00-11:15am	Break	
Session II: Evolving practice and concept on HCC - Chairs: Stephen Chan, Kenneth Chok		
11:15-11:40am	How to run MDT effectively: Round-table discussion	Surgical: K Chok (HK) and P Chow (SG) Oncology/Hepatology: M Reig (Spain), Hsu Chiun (Taiwan) Radiologist: Hanyu Jiang (China)
11:40-12:00n	Conversion therapy: Do we have consensus	Kenneth Chok (HK)
12:00n-12:20pm	How to start big-data research	Grace Wong (HK)
12:20-12:40pm	Q&A	
12:40-2pm	Lunch	
Section III: Practical tips to develop your academic career - Chairs: Hsu Chiun, Landon Chan		
2:00-2:20pm	Understanding scientific data: What clinician should know?	Carmen Wong (Hong Kong)
2:20-2:40pm	The life of a clinician-scientist	Takahiro Kodama (Japan)
2:40-3:00pm	Q&A	
3:10-3:30pm	Publication in high-impact journals	Stephen Chan (Hong Kong)
3:30-4:00pm	Q&A & break	
4:00-4:20pm	Academic presentation: The art and science	Hsu Chiun (Taiwan)
4:20-4:40pm	Understanding the terminology and modality of radiation	Landon Chan (Hong Kong)
4:40-5:00pm	Q&A	
5:00-5:15pm	Closing Pre-Conference Masterclass	Hsu Chiun and Pierce Chow

Thank you to our ILCA Pre-Conference Masterclass Sponsors





SCIENTIFIC PROGRAMME

DAY 1 | WEDNESDAY, 19TH NOVEMBER 2025

11:00 – 11:15	ILCA AC2025 Opening Ceremony Tim Meyer, ILCA President, MD, PhD, (UK)
11:15 – 13:00	Advances In Systemic Therapy & Encore Presents 11.15 – 11.20 Introduction from session chairs Lorenza Rimassa, MD (Italy) Antonio d'Alessio, PhD (UK) 11.20 – 11.30 Antonio d'Alessio, PhD (UK) Neoadjuvant immunotherapy for HCC: how to move the field forward 11.30 – 11.40 Stephen Chan, MD, PhD, FAHA (Hong Kong) Novel systemic therapy for HCC 11.40 – 11.50 Riad Salem, MD (USA) The future of LRT in the era of combination therapy 11.50 – 12.00 Lorenza Rimassa, MD (Italy) Systemic therapy for CCA: Today & Tomorrow (clinical focus) 12.00 – 12.10 Questions & answers 12.10 – 12.50 encore presentations to be announced and presented. 12.50 – 13.00 Questions & answers
13:00 – 14:00	Lunch
13.30 – 14.00	Y-ILCA Career Development Roundtables, organised by the Y-ILCA Committee Chair: Antonio d'Alessio, PhD (UK) Experts for Basic Science & Translational Research Daniela Sia, MD, USA Valerie Chew, MD, PhD, Singapore Experts for Clinical Chiara Braconi, MD, PhD (UK) Stephen Chan, MD, PhD, FAHA (Hong Kong)





SCIENTIFIC PROGRAMME

DAY 1 | Wednesday, 19th November 2025

14.00 – 14.30	Legacy Session: Past, Present and Future Chair: Tim Meyer, MD, PhD, ILCA Actual President (UK) ILCA Founding Board and first ILCA President Jordi Bruix, MD (Spain) ILCA Past President Richard Finn, MD (USA) ILCA Past President Jessica Zucman-Rossi, MD (France) Stephen Chan, MD, PhD, FAHA (Hong Kong) ILCA President Elect
14.30 – 16.00	General Session 1 - Molecular Pathogenesis, Cell Biology and Translational Research and Poster blast 4 oral presentations from ILCA AC2025 accepted abstracts 8 Poster Blasts - 8 selected poster presenters will introduce their poster in «3 minutes pitch».
16:00 - 16:30	Coffee Break & Networking
16.30 – 17.30	Translation session on HCC/CCA risk and prevention Chairs: Valerie Chew, MD, PhD (Singapore) Carmen Wong, MD (Hong Kong) Multimomics stratification of HCC towards biomarkers discovery Irene Ng, MD (Hong Kong) Translational breakthroughs for HCC treatment and prevention (TBC) Tim Greten, MD (USA) New insights in risk and prevention of CCA Sumera Ilyas, MD (USA) Genetic mutations that predispose to CCA Jessica Zucman-Rossi, MD (France)
17:30 – 18:30	Poster Tour & Welcome Reception





SCIENTIFIC PROGRAMME

DAY 2 | Thursday, 20th November 2025

09.30 – 10.30	Translation session on HCC/CCA treatment - joint session with CCF (Cholangiocarcinoma Foundation)
	09.30 - 09.32 Introduction from session chairs Tim Greten, MD (USA) Daniela Sia, MD (USA)
	09.32 - 09.44 New systemic therapy landscapes for BTC (focus on translational) Chiara Braconi, MD, PhD (UK)
	09.44 - 09.56 Organoids and translational models of iCCA Daniela Sia, MD (USA)
	09.56 - 10.08 Impact of gut microbiome in nonalcoholic steatohepatitis-associated hepatocellular carcinoma Yu Jun, MD, FAHA (Hong Kong)
	10.08 - 10.20 Immune Cells as Predictive Biomarkers for Immunotherapy Response in HCC and CCA Gao Qiang, MD, PhD (China)
10.30 – 11.00	10.20 - 10.30 Questions & answers
	Coffee Break & Networking
11.00 – 11.30	ILCA Advocacy: Empowerment of Patients in MDT Chair: Manon Allaire, Dr (France)
	11.00 - 11.10 Ken Wong, MD (Hong Kong)
	11.10 - 11.20 Chan Leong Tat, MD (Hong Kong)
11.30 – 12.00	11.20 - 11.30 Neus Llarch (Spain)
	Presidential Address and Awards Ceremony • Nelson Fausto Award Announcement • Junior investigator Awards: • Best oral presentation (clinical) • Best oral presentation (basic/translational) • Best poster (clinical) • Best poster (basic/translational)



SCIENTIFIC PROGRAMME

DAY 2 | Thursday, 20th November 2025

12.00 – 13.00	General Session 2: Epidemiology, Staging and Prognosis 4 oral presentations from ILCA AC25 accepted abstracts.
13.00 – 14.00	Roche Lunch Industry Symposium
14.00 – 15.00	Surveillance - Joint session with KLCA (Korean Liver Cancer Association) 14.00 – 14.02 Introduction from session chairs Neehar Parikh, MD, MS (USA) June Sung Lee, MD (South Korea) 14.02 -14.14 Risk stratification in patients undergoing surveillance: Anything ready for prime time in 2025? Pierre Nahon, MD (France) 14.14 - 14.26 Emerging imaging-based strategies for HCC surveillance So Yeon Kim, MD (South Korea) 14.26 - 14.38 Role for CCA surveillance Shahid A Khan, MD (UK) 14.38 - 14.50 Emerging biomarker panels for HCC surveillance Soon Sun Kim, MD, PhD (South Korea) 14.50 - 15.00 Questions & answers
15.00 – 16.00	General Session 3: Surveillance and Diagnosis 4 oral presentations from ILCA AC2025 accepted abstracts.
16.00 – 16.45	Coffee Break & Networking General Assembly (Members only)
16.45 – 17.45	Tumor Board Anjana Pillai, MD (USA) David Pinato, MD, PhD, (UK) Edward Kim, MD (USA) Tiffany Wong, MD (Hong Kong)
17.45 – 18.45	AstraZeneca Industry Symposium
18.45 – 19.15	Y-ILCA Masterclass, organised by the Y-ILCA Committee How to publish your paper on a high-impact journal: tips from the editor Chairs: Joycelyn Lee, MD (Singapore) and Ryan Poting Lin, MD (Taiwan) Jessica Zucman Rossi, MD (France) Masatoshi Kudo, MD, PhD (Japan)



SCIENTIFIC PROGRAMME

DAY 3 | Friday, 21st November 2025

08.30 – 09.30	GUERBET Industry Symposium
09.30 – 10.30	Surgery and Transplant Oncology - Joint Session With CLCS (China Anti-Cancer Association Liver Cancer) Introduction from session chairs Gonzalo Sapisochin, MD, PhD, MSc (Spain) Ming Kuang, MD, PhD (China) 09.30- 09.42 Update on criteria for resectability of HCC and CCA Gonzalo Sapisochin, MD, PhD, MSc (Spain) 09.42 -09.54 Neoadjuvant and adjuvant therapies for HCC - what the future holds - ?? Ming Kuang, MD, PhD (China) 09.54 -10.06 Update on Transplant for malignancies other than HCC - CRC mets and CCA - ?? Karim Halazum, MD(USA) 10.06 -10.18 Downstaging for HCC - is there a limit? Huichuan Sun, Dr (China) 10.18 -10.30 Questions & Answers
10.30 – 11.00	Coffee Break & Networking
11.00 – 11.30	Basic State of the Art Senescence in HCC Michael Karin, MD, PhD (USA)
11.30 – 12.30	General Session 4: Surveillance and diagnosis 4 oral presentations from ILCA AC2025 accepted abstracts.
12.30 – 13.15	Survivorship and patient-reported outcomes Introduction from session chairs Maria Reig, MD, PhD (Spain) 12:30 -12:40 Evidence based practice for palliative care for Liver Cancer Ken Liu, MD (Australia) 12:40 - 12:50 Caring Beyond Cure: The Vital Role of Nurses in Long-Term Survivorship Neus Llarch (Spain)





SCIENTIFIC PROGRAMME

DAY 3 | Friday, 21st November 2025

12.30 – 13.15	12.50 -13.00 Liver Cancer and Chroni IRAE: Navigating the therapeutic Tightrope Jean Charles Nault, MD (France) 13.00 – 13.15 Roundtable discussion
13.15 – 14.15	EISAI Lunch Industry Symposium
14.15 – 15.00	ILCA Debates 14.15 -14.17 Introduction from session chairs Clinical debate: Patients with Vp1/2 should be treated with locoregional/surgical therapies Neehar Parikh, MD, MS (USA) Clinical debate: Patients with Vp1/2 should be treated with systemic therapies David Pinato, MD, PhD, (UK) Basic Science Debate: AI will become the PI (against) Carmen Wong, MD (Hong Kong) Basic Science Debate: AI will become the PI (for) Julien Calderaro, PhD, MCU-PH (France)
15.00 – 16.10	DIAGNOSIS & STAGING -joint session with INASL (India National Association for Study of the Liver) 15.00 -15.02 Introduction from session chairs Neil Mehta, MD (USA) Anjana Pillai, MD (USA) 15.02 - 15.17 Pathological Diagnosis of HCC Valerie Paradis, MD, PhD (France) 15.17 -15.37 Novel PET Modalities in HCC Anand Kulkarni, MD, FACC (India) 15.37 – 15.57 Biomarkers in HCC Ashish Kumar, MD, PhD (India) 15.57 – 16.07 Prognostic and predictive value of imaging biomarkers Julius ChapiroMD, PhD (USA)
16.30 – 16.40	Closing Address Tim Meyer, ILCA President, MD (UK)



THANK YOU TO OUR SPONSORS AND SUPPORTERS FOR THEIR SUPPORT

ILCA 2025 PRINCIPAL SPONSOR



ILCA 2025 PREMIUM SPONSOR



ILCA 2025 CONFERENCE SPONSORS



ILCA 2025 CONFERENCE SUPPORTERS



ILCA 2025 INDUSTRY PARTNERS





INDUSTRY SYMPOSIA



Thursday, 20th November 2025, 13.00 – 14.00

Roche Lunch Industry Symposium

Title: Redefining What's Possible: The Evolution of HCC Treatment and Care Today

Chair & Faculty: Stephen Chan, Hui-Chuan Sun, Yonghong Zhang, Maria Reig



Thursday, 20th November 2025, 17.45 -18.45

AstraZeneca Industry Symposium

Title: Advancing patient care for hepatobiliary cancers: emerging treatments and future outlooks

Panel: Anjana Pillai, David Tai, Chi-Leung Chiang



Friday, 21st November 2025, 08.30 – 09.30

Guerbet Industry Symposium

Title: Downstaging Strategies in HCC: Bridging the Gap to curative therapies

Panel: Prof Valérie Vilgrain, Prof Maxime Ronot, Dr. Julius Chapiro, Dr Richard Fin



Friday, 21st November 2025, 13.15 – 14.15

Eisai Lunch Industry Symposium

Title: Navigating Complexity: Multimodal Innovations in Unresectable Hepatocellular Carcinoma (HCC)

Panel: Prof. Stephen Chan, Prof Krittiya Korphaisarn, Prof Josep M Llovet, Prof Masatoshi Kudo, Prof SUN Hui Chuan



JOIN THE **ILCA COMMUNITY AND
REGISTER FOR THE CONFERENCE NOW!
WE CAN'T WAIT TO SEE YOU !**

Contact us for more details:
International Liver Cancer Association (ILCA)
Avenue des arts, 47
B-1000 Brussels – Belgium

Tel: +32 (0)2 320 2531
Email: info@ilca-online.org
Website: www.ilca-online.org

